Full text biomedical articles

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia

Anuhar Chaturvedi, Charu Gupta, Razif Gabdoulline, Nora M. Borchert, Ramya Goparaju, Stefan Kaulfuss, Kerstin Gorlich, Renate Schottmann, Basem Othman, Julia Welzenbach, Olaf Panknin, Markus Wagner, Robert Geffers, Arnold Ganser, Felicitas Thol, Michael Jeffers, Andrea Haegebarth, Michael Heuser
Haematologica. 2021 Feb 1; 106(2): 565–573. Published online 2020 Apr 2. doi: 10.3324/haematol.2019.236992


Article   |   PubReader   |   PDF–2.2M   |   Cite

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Christopher R. Cogle, Bart L. Scott, Thomas Boyd, Guillermo Garcia-Manero
Oncologist. 2015 Dec; 20(12): 1404–1412. Published online 2015 Oct 13. doi: 10.1634/theoncologist.2015-0165


Article   |   PubReader   |   PDF–810K   |   Cite

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia

Kishan K. Patel, Amer M. Zeidan, Rory M. Shallis, Thomas Prebet, Nikolai Podoltsev, Scott F. Huntington
Blood Adv. 2021 Feb 23; 5(4): 994–1002. Published online 2021 Feb 16. doi: 10.1182/bloodadvances.2020003902


Article   |   PubReader   |   PDF–963K   |   Cite

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

Chengyin Min, Nathan Moore, Jeffrey R. Shearstone, Steven N. Quayle, Pengyu Huang, John H. van Duzer, Matthew B. Jarpe, Simon S. Jones, Min Yang
PLoS One. 2017; 12(1): e0169128. Published online 2017 Jan 6. doi: 10.1371/journal.pone.0169128


Article   |   PubReader   |   PDF–3.6M   |   Cite

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Lisa Pleyer, Hartmut Döhner, Hervé Dombret, John F. Seymour, Andre C. Schuh, CL Beach, Arlene S. Swern, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva M. Autzinger, Alois Lang, Klaus Geissler, Daniela Voskova, Wolfgang R. Sperr, Sabine Hojas, Inga M. Rogulj, Johannes Andel, Richard Greil
Int J Mol Sci. 2017 Feb; 18(2): 415. Published online 2017 Feb 15. doi: 10.3390/ijms18020415


Article   |   PubReader   |   PDF–1.3M   |   Cite

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Mikkael A. Sekeres, Megan Othus, Alan F. List, Olatoyosi Odenike, Richard M. Stone, Steven D. Gore, Mark R. Litzow, Rena Buckstein, Min Fang, Diane Roulston, Clara D. Bloomfield, Anna Moseley, Aziz Nazha, Yanming Zhang, Mario R. Velasco, Rakesh Gaur, Ehab Atallah, Eyal C. Attar, Elina K. Cook, Alyssa H. Cull, Michael J. Rauh, Frederick R. Appelbaum, Harry P. Erba
J Clin Oncol. 2017 Aug 20; 35(24): 2745–2753. Published online 2017 May 9. doi: 10.1200/JCO.2015.66.2510


Article   |   PubReader   |   PDF–893K   |   Cite

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Giovanni Martinelli, Jose Falantes, Richard Noppeney, Richard M. Stone, Mark D. Minden, Heidi McIntyre, Steve Songer, Lela M. Lucy, C. L. Beach, Hartmut Döhner
Blood. 2015 Jul 16; 126(3): 291–299. Prepublished online 2015 May 18. doi: 10.1182/blood-2015-01-621664


Article   |   PubReader   |   Cite

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

Betül Oran, Marcos de Lima, Guillermo Garcia-Manero, Peter F. Thall, Ruitao Lin, Uday Popat, Amin M. Alousi, Chitra Hosing, Sergio Giralt, Gabriela Rondon, Glenda Woodworth, Richard E. Champlin
Blood Adv. 2020 Nov 10; 4(21): 5580–5588. Published online 2020 Nov 10. doi: 10.1182/bloodadvances.2020002544


Article   |   PubReader   |   PDF–1.0M   |   Cite

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl-Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva-Maria Autzinger, Alois Lang, Klaus Geissler, Daniela Voskova, Dietmar Geissler, Wolfgang R. Sperr, Sabine Hojas, Inga M. Rogulj, Johannes Andel, Richard Greil
J Hematol Oncol. 2016; 9: 39. Published online 2016 Apr 16. doi: 10.1186/s13045-016-0263-4


Article   |   PubReader   |   PDF–694K   |   Cite

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

John F. Seymour, Hartmut Döhner, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Jose Falantes, Richard M. Stone, Mark D. Minden, Jerry Weaver, Steve Songer, C. L. Beach, Hervé Dombret
BMC Cancer. 2017; 17: 852. Published online 2017 Dec 14. doi: 10.1186/s12885-017-3803-6


Article   |   PubReader   |   PDF–1.8M   |   Cite

Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study

Byung-Hyun Lee, Ka-Won Kang, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Hojoon Choi, Se Ryeon Lee, Hwa Jung Sung, Byung Soo Kim, Chul Won Choi, Yong Park
Sci Rep. 2020; 10: 39. Published online 2020 Jan 8. doi: 10.1038/s41598-019-56642-1


Article   |   PubReader   |   PDF–1.7M   |   Cite

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

Hartmut Döhner, Anna Dolnik, Lin Tang, John F. Seymour, Mark D. Minden, Richard M. Stone, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Valeria Santini, Paresh Vyas, C. L. Beach, Kyle J. MacBeth, Barry S. Skikne, Steve Songer, Nora Tu, Lars Bullinger, Hervé Dombret
Leukemia. 2018; 32(12): 2546–2557. Published online 2018 Oct 1. doi: 10.1038/s41375-018-0257-z


Article   |   PubReader   |   PDF–3.3M   |   Cite

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Lisa Pleyer, Sonja Burgstaller, Michael Girschikofsky, Werner Linkesch, Reinhard Stauder, Michael Pfeilstocker, Martin Schreder, Christoph Tinchon, Thamer Sliwa, Alois Lang, Wolfgang R. Sperr, Peter Krippl, Dietmar Geissler, Daniela Voskova, Konstantin Schlick, Josef Thaler, Sigrid Machherndl-Spandl, Georg Theiler, Otto Eckmüllner, Richard Greil
Ann Hematol. 2014; 93(11): 1825–1838. Published online 2014 Jun 21. doi: 10.1007/s00277-014-2126-9


Article   |   PubReader   |   PDF–939K   |   Cite

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

R. F. Schlenk, D. Weber, W. Herr, G. Wulf, H. R. Salih, H. G. Derigs, A. Kuendgen, M. Ringhoffer, B. Hertenstein, U. M. Martens, M. Grießhammer, H. Bernhard, J. Krauter, M. Girschikofsky, D. Wolf, E. Lange, J. Westermann, E. Koller, S. Kremers, M. Wattad, M. Heuser, F. Thol, G. Göhring, D. Haase, V. Teleanu, V. Gaidzik, A. Benner, K. Döhner, A. Ganser, P. Paschka, H. Döhner
Leukemia. 2019; 33(8): 1923–1933. Published online 2019 Feb 6. doi: 10.1038/s41375-019-0395-y


Article   |   PubReader   |   PDF–561K   |   Cite

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

Courtney L. Jones, Brett M. Stevens, Angelo D'Alessandro, Julie A. Reisz, Rachel Culp-Hill, Travis Nemkov, Shanshan Pei, Nabilah Khan, Biniam Adane, Haobin Ye, Anna Krug, Dominik Reinhold, Clayton Smith, James DeGregori, Daniel A. Pollyea, Craig T. Jordan
Cancer Cell. Author manuscript; available in PMC 2019 Nov 12.
Published in final edited form as: Cancer Cell. 2018 Nov 12; 34(5): 724–740.e4. doi: 10.1016/j.ccell.2018.10.005


Article   |   PubReader   |   PDF–2.7M   |   Cite

Azacitidine.

IARC Monogr Eval Carcinog Risks Hum. 1990; 50: 47–63.


Article   |   PubReader   |   Cite

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

Bruno C. Medeiros, Kelly McCaul, Suman Kambhampati, Daniel A. Pollyea, Rajat Kumar, Lewis R. Silverman, Andrea Kew, Lalit Saini, CL Beach, Ravi Vij, Xiwei Wang, Jim Zhong, Robert Peter Gale
Haematologica. 2018 Jan; 103(1): 101–106. Prepublished online 2017 Nov 2. doi: 10.3324/haematol.2017.172353


Article   |   PubReader   |   PDF–590K   |   Cite

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

Pierre Bories, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, Julien Plenecassagnes, Isabelle Luquet, Véronique De Mas, Thomas Filleron, Manon Cassou, Audrey Sarry, Luc-Matthieu Fornecker, Célestine Simand, Sarah Bertoli, Christian Recher, Eric Delabesse
PLoS One. 2020; 15(10): e0238795. Published online 2020 Oct 1. doi: 10.1371/journal.pone.0238795


Article   |   PubReader   |   PDF–1.1M   |   Cite

Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia

Santhosh K Sadashiv, Christie Hilton, Cyrus Khan, James M Rossetti, Heather L Benjamin, Salman Fazal, Entezam Sahovic, Richard K Shadduck, John Lister
Cancer Med. 2014 Dec; 3(6): 1570–1578. Published online 2014 Aug 16. doi: 10.1002/cam4.321


Article   |   PubReader   |   PDF–161K   |   Cite

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

Rami Komrokji, Arlene S. Swern, David Grinblatt, Roger M. Lyons, Magnus Tobiasson, Lewis R. Silverman, Hamid Sayar, Ravi Vij, Albert Fliss, Nora Tu, Mary M. Sugrue
Oncologist. 2018 Feb; 23(2): 159–170. Published online 2017 Nov 8. doi: 10.1634/theoncologist.2017-0215


Article   |   PubReader   |   PDF–690K   |   Cite